Joseph A O'Donoghue Selected Research

Joseph A O'Donoghue Research Topics

Disease

26	Neoplasms (Cancer) 01/2021 - 02/2002
8	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 07/2008
8	Hypoxia (Hypoxemia) 09/2017 - 04/2005
4	Colorectal Neoplasms (Colorectal Cancer) 06/2013 - 08/2011
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2020 - 01/2019
3	Head and Neck Neoplasms (Head and Neck Cancer) 09/2017 - 06/2013
2	Kidney Neoplasms (Kidney Cancer) 04/2012 - 08/2004
1	Multiple Myeloma 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2019
1	Hepatocellular Carcinoma (Hepatoma) 03/2018
1	Adenocarcinoma 01/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Necrosis 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2012
1	Colonic Neoplasms (Colon Cancer) 12/2011
1	Neuroblastoma 05/2002

Drug/Important Bio-Agent (IBA)

10	AntigensIBA 12/2019 - 05/2007
7	Radioisotopes (Radionuclides)IBA 01/2021 - 02/2002
5	Monoclonal AntibodiesIBA 12/2019 - 02/2002
4	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 12/2020 - 07/2008
4	Biomarkers (Surrogate Marker)IBA 12/2019 - 03/2011
4	pimonidazoleIBA 03/2011 - 08/2007
3	AntibodiesIBA 01/2019 - 12/2011
3	fluoromisonidazoleIBA 09/2017 - 04/2005
2	Biological ProductsIBA 01/2021 - 09/2017
2	RadiopharmaceuticalsIBA 01/2021 - 01/2017
2	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2020 - 01/2019
2	Chelating AgentsIBA 01/2020 - 07/2008
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2019 - 10/2015
2	human ERBB2 proteinIBA 01/2018 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2017 - 10/2015
2	Oxygen (Dioxygen)IBA 01/2017 - 09/2006
2	Galactose (Galactopyranose)FDA LinkGeneric 06/2013 - 02/2010
2	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 03/2011 - 08/2007
2	Bromodeoxyuridine (BrdU)IBA 04/2010 - 08/2007
2	carbogenIBA 04/2010 - 08/2007
2	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 08/2005 - 04/2005
1	Peptide Receptors (Peptide Receptor)IBA 12/2020
1	daratumumabIBA 01/2020
1	Deferoxamine (Desferal)FDA LinkGeneric 01/2020
1	ZirconiumIBA 01/2020
1	Aligeron (AS 2)IBA 01/2020
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 12/2019
1	somatostatin receptor 2IBA 12/2019
1	Immunoconjugates (Immunoconjugate)IBA 11/2019
1	Indicators and Reagents (Reagents)IBA 11/2019
1	Prostate-Specific Antigen (Semenogelase)IBA 11/2019
1	GlypicansIBA 03/2018
1	codrituzumabIBA 03/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	zirconium-89-trastuzumabIBA 01/2018
1	palladium-bacteriopheophorbideIBA 01/2017
1	BombesinIBA 01/2017
1	BacteriochlorophyllsIBA 01/2017
1	NitrogenIBA 01/2017
1	PalladiumIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	padeliporfinIBA 01/2017
1	Bombesin Receptors (Bombesin Receptor)IBA 01/2017
1	89Zr-Df-IAB2MIBA 12/2016
1	IndiumIBA 01/2015
1	vadimezanIBA 03/2011
1	Glucose (Dextrose)FDA LinkGeneric 04/2010
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2010
1	azomycinIBA 02/2010
1	Proteins (Proteins, Gene)FDA Link 08/2007
1	Carbonic Anhydrase IXIBA 08/2007
1	Isoflurane FDA LinkGeneric 09/2006
1	PhosphatidylserinesIBA 05/2002
1	Annexin A5IBA 05/2002

Therapy/Procedure

9	Therapeutics 01/2021 - 09/2006
5	Castration 11/2019 - 07/2008
4	Radioimmunotherapy 01/2012 - 08/2004
3	Radiotherapy 01/2017 - 02/2002
2	Immunotherapy 01/2020 - 03/2018
2	Drug Therapy (Chemotherapy) 01/2018 - 06/2008
2	Aftercare (After-Treatment) 01/2012 - 03/2011
1	Precision Medicine 01/2021
1	Chemoradiotherapy 09/2017
1	Photochemotherapy (Photodynamic Therapy) 01/2017
1	Anesthesia 09/2006